Trial Profile
Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children From 3 to Less Than 18 Years of Age With GT-1 to -6 Chronic Hepatitis C (CHC) Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 16 Apr 2021 Status changed from completed to discontinued.
- 20 Nov 2020 Status changed from active, no longer recruiting to completed.